Callan Family Office LLC Makes New $324,000 Investment in United Therapeutics Co. (NASDAQ:UTHR)

Callan Family Office LLC acquired a new position in shares of United Therapeutics Co. (NASDAQ:UTHR) during the fourth quarter, Holdings Channel reports. The fund acquired 918 shares of the biotechnology company’s stock, valued at approximately $324,000.

A number of other hedge funds have also recently bought and sold shares of the company. Geode Capital Management LLC boosted its holdings in shares of United Therapeutics by 4.3% in the 3rd quarter. Geode Capital Management LLC now owns 1,094,015 shares of the biotechnology company’s stock worth $391,459,000 after buying an additional 45,566 shares during the last quarter. FMR LLC boosted its holdings in shares of United Therapeutics by 41.1% in the 3rd quarter. FMR LLC now owns 1,077,628 shares of the biotechnology company’s stock worth $386,168,000 after buying an additional 314,004 shares during the last quarter. Pacer Advisors Inc. boosted its holdings in shares of United Therapeutics by 5.5% in the 4th quarter. Pacer Advisors Inc. now owns 597,634 shares of the biotechnology company’s stock worth $210,869,000 after buying an additional 30,931 shares during the last quarter. Janus Henderson Group PLC boosted its holdings in shares of United Therapeutics by 12.3% in the 3rd quarter. Janus Henderson Group PLC now owns 460,419 shares of the biotechnology company’s stock worth $164,978,000 after buying an additional 50,409 shares during the last quarter. Finally, Assetmark Inc. boosted its holdings in shares of United Therapeutics by 2.2% in the 4th quarter. Assetmark Inc. now owns 429,160 shares of the biotechnology company’s stock worth $151,425,000 after buying an additional 9,203 shares during the last quarter. 94.08% of the stock is owned by hedge funds and other institutional investors.

United Therapeutics Stock Up 0.6 %

Shares of UTHR opened at $317.87 on Tuesday. The business’s 50-day moving average price is $353.73 and its 200-day moving average price is $359.80. United Therapeutics Co. has a twelve month low of $221.53 and a twelve month high of $417.82. The stock has a market cap of $14.28 billion, a PE ratio of 13.96, a P/E/G ratio of 0.97 and a beta of 0.64.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings results on Wednesday, February 26th. The biotechnology company reported $6.19 earnings per share for the quarter, beating the consensus estimate of $6.10 by $0.09. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The firm had revenue of $735.90 million for the quarter, compared to analysts’ expectations of $734.74 million. During the same period in the prior year, the business posted $4.36 earnings per share. Analysts expect that United Therapeutics Co. will post 24.48 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

UTHR has been the topic of a number of research analyst reports. HC Wainwright reissued a “buy” rating and issued a $425.00 price target on shares of United Therapeutics in a report on Thursday, February 27th. UBS Group upped their price objective on shares of United Therapeutics from $415.00 to $475.00 and gave the company a “buy” rating in a report on Wednesday, January 8th. Finally, StockNews.com downgraded shares of United Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Thursday, February 27th. One analyst has rated the stock with a sell rating, two have issued a hold rating and ten have given a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $388.25.

Insider Activity

In related news, Director Nilda Mesa sold 255 shares of the company’s stock in a transaction that occurred on Monday, December 30th. The shares were sold at an average price of $355.77, for a total value of $90,721.35. Following the transaction, the director now directly owns 5,528 shares in the company, valued at approximately $1,966,696.56. This represents a 4.41 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Louis W. Sullivan sold 26,209 shares of the company’s stock in a transaction that occurred on Wednesday, December 18th. The stock was sold at an average price of $373.22, for a total transaction of $9,781,722.98. Following the completion of the transaction, the director now owns 5,051 shares in the company, valued at approximately $1,885,134.22. This trade represents a 83.84 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 116,464 shares of company stock worth $42,396,244 over the last ninety days. Company insiders own 11.90% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.